With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
Aakash Desai, MBBS, MPH
Advertisement
Articles by Aakash Desai, MBBS, MPH
Advertisement
Latest Updated Articles
- Neulasta Onpro: A Coup de Grâce?
Published: March 13th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color
4
FDA Approves Second Generic Mifepristone Pill for Abortion
5
